Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 7/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | MTOR | P42345 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930176 | 0.93 | GAK (0.63) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4123000 | 0.90 | PDE4A (0.56) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3921136 | 0.88 | PDE4A (0.54) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4108773 | 0.87 | GAK (0.55) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4101387 | 0.87 | ALDH1A1 (0.55) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4101506 | 0.86 | NOS1 (0.45) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4116494 | 0.85 | GAK (0.52) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4114035 | 0.81 | NOS1 (0.46) | GAKPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4528710 | 0.81 | PIK3CD (0.54) | PDE4APDE4BPDE4CPDE4DNOS1 | |
| SCHEMBL4114369 | 0.81 | PDE4A (0.65) | GAKPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | GAK 1134/4885PDE4A 1370/4885PDE4B 1438/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | GAK 1295/4885PDE4A 112/4885PDE4B 313/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | GAK 1295/4885PDE4A 112/4885PDE4B 313/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | GAK 1295/4885PDE4A 112/4885PDE4B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.